Willow Biosciences Inc (TSX:WLLW, OTCQB:CANSF) has announced the completion of its previously announced offering of convertible debenture units on a non-brokered private placement basis for aggregate proceeds of C$800,000.
The offering was led by insiders including members of the Board of Directors and the senior management team, who subscribed for a total of C$515,000.
Proceeds from the offering are targeted at the commercialization and development of its pipeline of products, working capital and general corporate purposes.
Details of the offering can be found here.